1 Program in Epidemiology, Fred Hutchinson Cancer Research Center, Seattle, WA
2 Department of Epidemiology, School of Public Health and Community Medicine, University of Washington, Seattle, WA
Correspondence to Dr. Victoria L. Holt, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North (M4 B874), PO Box 19024, Seattle, WA 98109-1024 (e-mail: vholt{at}u.washington.edu).
Received for publication August 12, 2004. Accepted for publication October 27, 2004.
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
body mass index; case-control studies; marijuana smoking; ovarian cysts; smoking
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Epidemiologic studies have identified few risk factors for the development of functional ovarian cyst; clinicians have posited that altered serum gonadotropin levels cause the condition (2). Cigarette smoking is known to affect gonadotropins, ovarian hormones, and ovarian function (3
5
), yet the results of previous epidemiologic studies of this exposure in relation to cyst development are somewhat mixed. Smoking was found to significantly increase ovarian cyst risk in two US studies, a retrospective cohort study with self-reported disease ascertainment (6
) and a small case-control study that used existing medical records for case finding and data collection (7
). Conversely, an Italian hospital-based case-control study reported no significant associations with current or former smoking (8
). Although marijuana also affects gonadotropin levels and ovarian function (9
), to our knowledge there has been no epidemiologic research on the possible association between marijuana use and ovarian cyst development.
We conducted this analysis to investigate further the relations between cigarette and marijuana smoking and the risk of functional ovarian cyst. Because the results of the cohort study noted above suggested that the effect of cigarette smoking on cyst risk may be stronger among leaner women, a primary goal was to determine whether heterogeneity of effect across body mass index (BMI) categories existed.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Group Health Cooperative lists of all women aged 1839 years enrolled in the health maintenance organization between January 1, 1990, and June 30, 1994, were the basis for our control group selection. We chose potential controls randomly from these lists, stratified by 5-year age groups, with the number of controls in each age group proportional to the number of cases in that age group. Reference months were assigned to potential controls according to the distribution of cases' reference months. After telephone query of potential controls, we excluded women who did not speak English, had had a bilateral oophorectomy, were pregnant during the reference month, or had been enrolled in the Group Health Cooperative less than 6 months before the reference month.
After written informed consent was obtained, we were able to interview 586 of the 750 eligible potential cases (78.1 percent) and 757 of the 921 eligible potential controls (82.2 percent). All study protocols were approved by the Fred Hutchinson Cancer Research Center and the Group Health Cooperative human subjects review committees. For the analyses presented in this paper, we excluded three cases and two controls for whom interview data were unreliable. Additionally, we excluded 60 cases and 33 controls who had received an infertility diagnosis or had undergone infertility treatment, because ovarian cysts are associated with infertility treatment and these women's smoking habits may have changed as a result of an infertility diagnosis. A total of 523 cases and 722 controls remained for analysis. For 395 cases (75.5 percent), the ovarian cyst diagnosis was made during a clinic visit for cyst symptoms; for 128 cases (24.5 percent), the cyst was found incidentally.
Study participants were interviewed in person by trained female interviewers using a structured questionnaire to elicit a lifetime history of a variety of demographic, medical, and lifestyle factors. All interview information collected pertained to events or characteristics up until the reference month.
We asked participants whether they had smoked more than 100 cigarettes in their lifetime and, if so, at what age they began to smoke. If these women did not still smoke in the reference month, we obtained the age at which they had stopped. Additionally, we ascertained the average number of cigarettes smoked per day overall and in the 3 months before the reference month, and the total number of years of smoking before the reference month. For these analyses, we considered current cigarette smokers to be women who smoked in the 3 months before the reference month; former smokers were those who smoked at least 100 cigarettes in their lifetime but did not smoke in the 3 months before the reference month; and never smokers were those who smoked fewer than 100 cigarettes total in their lifetime.
Similarly, we asked participants whether they had ever smoked marijuana and, if so, at what age they first did so. We then ascertained how often these women smoked marijuana when they first began to smoke, and how much they smoked on a day during which they smoked. If the participant's marijuana smoking habits had ever changed, we ascertained the details noted above for each change in smoking habits up until the reference month. For the current analyses, we classified as marijuana never users women who had smoked marijuana fewer than five times in their lifetime; current users were women who smoked marijuana at least five times in their lifetime and who considered themselves marijuana smokers as of the reference month; and former users were women who had smoked marijuana at least five times and considered themselves not to be marijuana smokers as of the reference month. Alcohol consumption in the 12 months prior to the reference month was ascertained as part of a food frequency questionnaire.
Odds ratios and 95 percent confidence intervals for the associations of cigarette smoking and marijuana use with risk of a functional ovarian cyst were calculated by using unconditional logistic regression, with Stata statistical software (11). Two comparisons were made in the analyses of each exposure: 1) former versus never smoker and 2) current versus never smoker. We tested for effect modification by BMI (defined as weight (kg)/height (m2)) using the likelihood ratio test and categorizing BMI as recommended by the National Research Council's Committee on Diet and Health (12
): underweight (<20.0), normal weight (20.025.0), and overweight (>25.0). We found significant (p < 0.05) heterogeneity of effect by BMI for cigarette smoking but not for marijuana use; for consistency and to provide additional information, in this paper we present both sets of analyses separately by BMI category. We examined as potential confounders the following variables: race/ethnicity, marital status, educational level, income, marijuana use (for smoking analyses), cigarette smoking (for marijuana analyses), pregnancies, livebirths, spontaneous abortions, induced abortions, tubal sterilization, current oral contraceptive use, previous ovarian cyst, and alcohol consumption. We included potential confounding variables in the multivariate models if they were matching variables or changed the odds ratio for ovarian cyst risk associated with smoking or marijuana use by 10 percent or more (13
). Age, educational level, and reference year met these criteria for the smoking analyses; and age, cigarette smoking, and reference year met the criteria for the marijuana analyses.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
|
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In apparent contrast to the studies cited above, a hospital-based case-control study conducted in Milan, Italy, did not find a significant association between current or former smoking and cyst risk (8). However, in that study, the adjusted odds ratio for current smoking was 1.4, and the small number of cases (n = 68) and the use of hospitalized controls may have affected the results and their interpretation. Similarly, the authors of a cross-sectional clinical study of 335 randomly selected reproductive-age women undergoing transvaginal ultrasound examination reported no association between smoking and ovarian cysts in their population (14
). The power of that study was quite limited as well, and the authors found that 40.9 percent of the 22 women with cystic ovarian lesions were current smokers, compared with 22.7 percent of the 309 women without cysts.
To our knowledge, no prior study has investigated marijuana use in relation to functional ovarian cyst risk, either as a primary exposure or as a potential confounder of other associations. Although marijuana use did not confound our smoking analyses, we did find an increased ovarian cyst risk associated with marijuana use for underweight and normal-weight women. However, current marijuana use in our population was much less common than cigarette smoking, and our risk estimates were neither precise nor significant. Additionally, it is possible that marijuana users in our population smoked marijuana too infrequently to enable us to evaluate this potential association conclusively.
A major strength of the current health maintenance organization-based study was the large sample size, which enabled us to examine smokingovarian cyst relations precisely and test for effect modification. Rather than rely on a highly selective group of women who underwent surgery or ultrasound examination and were found not to have cysts, we chose controls randomly from Group Health Cooperative enrollment lists, assuring that they were representative of the well-defined population from which the cases arose. However, because we did not conduct diagnostic surgical or radiologic examinations of controls, the potential for inclusion of some number of undiagnosed cases in the control group existed in our study. Two cross-sectional studies of transvaginal ultrasound examination of randomly selected reproductive-age women found undiagnosed ovarian cysts in 67 percent of participants (14, 15
). The percentage of controls who were undiagnosed cases may be somewhat lower in our study population for two reasons. There are no financial barriers to obtaining medical care within the Group Health Cooperative, so any symptomatic enrollee is likely to obtain medical attention that would lead to diagnosis. Additionally, we required 6 months of Group Health Cooperative enrollment prior to the reference month to ensure that all participants had the opportunity to establish care. We found that 83 percent of our controls had had Group Health Cooperative medical visits within 12 months of the reference month, at which asymptomatic cysts could be diagnosed. Because the opportunity for diagnosis did not differ appreciably by smoking status or BMI, the presence of a small number of undiagnosed cysts in our control group would likely have resulted in only a slight bias of our results toward the null.
In contrast to two prior epidemiologic studies, we were able in this interview study to assess the ovarian cyst risk associated with current and former smoking separately. Similar to Parazzini et al. (8), we found higher risks for current smoking than for former smoking. Recognizing that decisions about the time since smoking cessation used to define subjects as former smokers may affect risk estimates (16
), we decided to classify women as former smokers if they had last smoked 3 or more months prior to the reference month, for two reasons. First, functional ovarian cysts are thought to arise fairly rapidly and may regress spontaneously over the course of a few months; therefore, the etiologically relevant period is likely to be the few months prior to cyst diagnosis. Second, the effect of smoking on serum levels of the gonadotropin follicle-stimulating hormone is seen in current smokers only (3
). Similarly, we did not use pack-years as a measurement of smoking behavior because neither duration nor intensity of past smoking affects levels of follicle-stimulating hormone.
To our knowledge, this study is the first to determine the existence of heterogeneity of the association between smoking and ovarian cyst by BMI. The potential for such effect modification was suggested by the results of Wyshak et al.'s 1988 study (6) of female college alumnae. In that study, the relation between smoking and cyst risk was stronger for women who had been athletes in college than for nonathletic women (relative risk = 1.90 vs. relative risk = 1.25). Because the authors found that former athletes were somewhat leaner than nonathletes, their finding of differential risk by college athleticism accords with our finding of effect modification by BMI.
Hormonal alterations associated with smoking, marijuana use, and BMI in reproductive-age women may help explain our findings. Smoking affects serum gonadotropin levels, alteration of which is the hypothesized mechanism of cyst development (2). Compared with nonsmokers, smokers have lower follicular-phase serum levels of the gonadotropin luteinizing hormone (4
) and higher levels of follicle-stimulating hormone (3
, 17
). Additionally, in reproductive-age women, smoking alters production and/or metabolism of estrogen (18
22
) and progesterone (4
, 23
). Finally, smoking affects menstrual function: smokers have shorter, more irregular cycles than nonsmokers do (24
), with increased likelihood of anovulation and short luteal phase (5
). Marijuana also affects reproductive hormones. Studies using 9-tetrahydrocannabinol, the active ingredient in marijuana, have shown a dose-related suppression of pulsatile luteinizing hormone secretion in rats (25
) and decreased progesterone levels during the luteal phase of the menstrual cycle, irregular cycle length, and anovulation in monkeys (26
, 27
). Similar effects have been seen in women who smoke marijuana: substantial suppression of plasma levels of luteinizing hormone during the luteal phase of the menstrual cycle (9
), shortened luteal phase and overall cycle length, and anovulation (28
). Increased BMI also has hormonal effects in reproductive-age women. Leptin, a hormone produced by adipose tissue with circulating levels closely correlated with degree of adiposity, counteracts the inhibitory effect of fasting on secretion of luteinizing hormone (29
); thus, we can speculate that leptin may counteract the luteinizing hormone-suppressive effects of smoking as well.
In summary, our results indicate that increased BMI may attenuate the adverse impact of smoking on the risk of functional ovarian cyst. Further investigation of the combined effect of smoking and BMI in relation to ovarian cysts as well as other hormonally related conditions in reproductive-age women is warranted.
![]() |
ACKNOWLEDGMENTS |
---|
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|